Steris PLC

This proposal asks shareholders to delegate to the Board or Audit Committee the authority to determine the remuneration of the Company’s Irish statutory auditor, Ernst & Young Chartered Accountants, rather than fixing that fee at the general meeting. Management is seeking this authorization because, under the Irish Companies Act, shareholder approval is one permissible mechanism to fix auditor remuneration, but it is common and practical for the Board or the Audit Committee (which oversees audit work) to determine the amount of compensation in the ordinary course once the auditor’s appointment is confirmed. Delegating fee-setting to the Audit Committee aligns control of audit-related costs with the committee responsible for auditor selection, independence monitoring, and oversight of audit services, enabling timely negotiation and approval of fee arrangements consistent with the audit plan and scope. The Board and Audit Committee emphasize that this delegation does not remove audit oversight or independence safeguards: the Audit Committee remains independent and has policies to pre-approve services and monitor non-audit fees to preserve auditor objectivity. From a governance perspective, this approach supports operational efficiency—especially for an international company with coordinated audit responsibilities across jurisdictions—while preserving the committee’s ability to report to shareholders about auditor engagement and fees. The principal trade-off for shareholders is reduced direct involvement in fixing the exact fee at the meeting, which management contends is outweighed by the Audit Committee’s subject-matter expertise and ability to address fee arrangements responsively. The Board’s uniform recommendation FOR the proposal reflects its view that the delegation is consistent with both Irish legal norms and good corporate governance practices for a U.S.-listed company incorporated in Ireland. Implementation risks are limited because the Audit Committee conducts formal evaluations, pre-approval processes, and receives independence disclosures from the auditor, and shareholders retain the right to appoint or remove auditors at future meetings.

This proposal is the Company’s annual non-binding advisory 'Say on Pay' vote, asking shareholders to approve the compensation of named executive officers as disclosed in the proxy statement. Management asks shareholders to endorse its executive pay program, which the Compensation and Organization Development Committee has designed to align pay with performance through a mix of base salary, annual incentive (tied to Adjusted EBIT and Adjusted free cash flow), and long-term equity (restricted stock and premium-priced options). The request is driven by Dodd-Frank and SEC rules and by the company’s commitment to regular shareholder feedback; the Board has historically held these advisory votes annually and will continue to do so, taking results into account when setting future compensation. While the vote is advisory and not binding, a favorable outcome supports the Board's conclusion that its compensation philosophy—emphasizing pay-for-performance, significant variable compensation, clawback provisions, equity ownership guidelines and double-trigger vesting—is consistent with shareholder interests; the Company reported strong Say-on-Pay support in prior years. Management’s rationale emphasizes that the metrics used (Adjusted EBIT and Adjusted FCF) incentivize both operating profitability and cash generation, and that the Compensation Committee retains discretion to consider individual and strategic factors. The key governance trade-offs include the non-binding nature of the vote and the committee’s discretion, but the committee commits to consider voting outcomes in subsequent pay decisions and to maintain transparency in compensation disclosures. For institutional investors evaluating this proposal, relevant considerations include the demonstrated linkage between pay and measurable financial metrics, historical shareholder support levels, and the presence of governance safeguards (clawbacks, ownership requirements, anti-hedging rules). The Board’s recommendation FOR reflects confidence that the current program appropriately balances incentive and retention objectives with shareholder alignment.

This resolution requests shareholder renewal of the Board’s authority to allot and issue shares (and grant rights to acquire shares) up to roughly 20% of the company’s issued ordinary share capital, a standard authorization under Irish company law. Management seeks this renewal because, unlike many U.S.-incorporated companies, Irish law requires shareholder approval for directors to allot shares; this resolution preserves the Board’s flexibility to effect financing, strategic acquisitions, equity-based employee compensation and other corporate transactions without seeking specific shareholder approval for each issuance. The 20% cap and the 15-month expiry are consistent with customary market practice and mirror the limits shareholders have approved previously; last year a similar renewal received overwhelming investor support. The resolution does not increase the authorized share capital or approve a specific issuance, and issuances remain subject to NYSE and SEC rules that constrain dilutive actions in specified circumstances. From a shareholder-protection standpoint, the proposal balances operational agility with limits on dilution (the 20% quantum and the time-limited nature of the authority) and continues to allow shareholders to vote on future renewals. The Board’s recommendation to vote FOR reflects the view that retaining the authority is essential for timely execution of strategic opportunities while maintaining standard governance controls, including Audit Committee and Board oversight of material financings. Investors assessing the trade-offs should consider the company’s capital allocation track record, recent share repurchases and dividend policy, and the company’s stated intent to use the authority primarily for acquisitions and specified capital investments if larger tranches are required.

This special resolution asks shareholders to renew the Board’s authority to disapply statutory pre-emption (pre-emptive) rights under Irish law for cash issuances up to approximately 20% of the issued share capital, with the important qualification that any portion above ~10% may only be used for acquisitions or specified capital investments announced contemporaneously (or completed within the prior six months). Under Irish law, pre-emption rights require that new cash issuances be offered pro rata to existing shareholders; disapplying them is common practice for listed companies to preserve strategic flexibility for timely acquisitions or financing. Management requests the renewal to maintain parity with market practice and to ensure the company can execute acquisition or capital-investment transactions quickly, while preserving a stricter constraint on the most dilutive projects (the >10% carve-out only for acquisitions/capital investments). Because this is a special resolution, it requires a 75% affirmative vote, reflecting the significant governance implications of disapplying pre-emption rights and providing shareholders a higher threshold to approve the delegation. The Board’s rationale is that the limit, the temporal cap (15 months), and the stated use restrictions provide a balance between operational flexibility and shareholder protection. Investors should weigh the company’s stated capital allocation policies, historical use of share issuance authorizations, and recent acquisition activity when evaluating this vote; the company disclosed prior-year shareholder support of ~94% for this authority. The Board recommends a FOR vote as it views the authority as essential to maintaining the ability to pursue acquisition-led growth and other strategic capital transactions promptly and on commercial terms.

This is a customary catch-all resolution that grants the appointed proxy holders authority to vote on any additional matters that may properly come before the meeting but were not specifically described in the proxy materials. Practically, companies include such a resolution so that routine procedural or unexpected items can be addressed without adjourning the meeting or soliciting supplemental proxies. Because no specific other proposals are known or disclosed, this item typically carries little substantive impact—the proxies will exercise their judgment and vote in a manner consistent with fiduciary duties and the Board’s guidance, and the inspector of elections will tabulate any votes. From a governance standpoint, shareholders should understand that this authority does not substitute for advance disclosure of material transactions or significant changes; material matters will ordinarily be publicly announced and, where required by law or listing rules, will be subject to separate shareholder approval. The Board did not provide an explicit recommendation for this open-ended item, reflecting that it is procedural in nature and contingent on whether any other business is properly presented. Institutional investors typically evaluate the inclusion of such a resolution as standard practice, with negligible governance consequence if no material matters are presented; if substantive items do arise at the meeting, shareholders should look to subsequent disclosure and filings for the details and rationale.